Publikationen

IZKF

Vorsitzender des IZKF-Vorstandes:
Prof. Dr. med. André Reis

Publikationen

2017

Thymidylate synthase is functionally associated with ZEB1 and contributes to the epithelial-to-mesenchymal transition of cancer cells.Siddiqui A, Vazakidou ME, Schwab A, Napoli F, Fernandez-Molina C, Rapa I, Stemmler MP, Volante M, Brabletz T, Ceppi P.J Pathol. 2017 Jun;242(2):221-233. doi: 10.1002/path.4897.

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, Kim J, Zhao JC, Putzbach W, Murmann AE, Chen Z, Chen W, Liu X, Salomon AR, Liu H, Weichselbaum RR, Yu J, Peter ME. Cell Rep. 2017 Mar 7;18(10):2373-2386. doi: 10.1016/j.celrep.2017.02.037

2015

Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P. The role of CD95 and CD95 ligand in cancer. Cell Death and Differentiation , 2015 Feb 6.

2014

Ceppi P, Hadji A, Kohlhapp FJ, Pattanayak A, Hau A, Liu X, Liu H, Murmann AE, Peter ME: CD95 and CD95L promote and protect cancer stem cells. Nature CommunicationsNov2014,5:5238.

Hadji A, Ceppi P*, Murmann AE, Brockway S, Pattanayak A, Bhinder B, Hau A, De Chant S, Parimi V, Kolesza P, Richards J, Chandel N, Djabalah H, Peter ME. Death Induced by CD95 or CD95 Ligand Elimination.  Cell Reports, 2014 Apr 10;7(1):208-22.

2013

Righi L, Bollito E, Ceppi P, Mirabelli D, Tavaglione V, Chiusa L, Porpiglia F,Brunelli M, Martignoni G, Terrone C, Papotti M. Prognostic role of bone sialoprotein in clear cell renal carcinoma. Anticancer Res. 2013;33(6):2679-87.

Ceppi P, Peter ME. microRNAs Regulate Both Epithelial-to-Mesenchymal Transition and Cancer Stem Cells. Oncogene. 2013 Mar 4.     

2012

Hau A, Ceppi P, Peter ME. CD95 Is Part of a let-7/p53/miR-34 Regulatory Network. PLoS One. 2012; 7(11):e49636.

Sprio AE, Di Scipio F, Ceppi P, Salamone P, Di Carlo F, Scagliotti GV, Papotti M, Ceccarelli A, Berta GN. Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation. Cancer Chemotherapy and Pharmacology 2012; 69(4):983-9.

Ceppi P, Rapa I, Lo Iacono M, Righi L, Giorcelli J, Pautasso M, Bille A, Ardissone F, Papotti M, Scagliotti GV. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer. International Journal of Cancer 2012, 130:1777-1786.

Kumarswamy R, Mudduluru G, Ceppi P, Papotti M, Allgayer H. MicroRNA-30a inhibits epithelial-to-mesenchymal transition and is down regulated in non-small cell lung cancer. International Journal of Cancer 2012; 130(9):2044-53.

2011

Lo Iacono M, Monica V, Saviozzi S, Ceppi P, Bracco E, Scagliotti GV. Aurora Kinase A gene expression is associated with lung cancer histological- subtypes and with tumor dedifferentiation. Journal of Translational Medicine. 2011 Jun 30;9:100.

Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. Regulation of Axl receptor thyrosine kinase expression by miR-34a and miR-199a/b in cancer cell lines. Oncogene. 2011 Jun 23;30(25):2888-99.

Lo Iacono M, Monica V, Saviozzi S, Ceppi P, Pandiscia S, Billè A, Bracco E, Papotti M and Scagliotti GV. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. Journal of Thoracic Oncology 2011 Mar;6(3):473-81.

2010

Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Molecular Cancer Research2010, 8:1207-1216.

Righi L, Papotti MG, Ceppi P, Bille` A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, and Selvaggi G. Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy. Journal of Clinical Oncology. 2010 Mar 20; 28: 1534-9.

Ceppi P**, Papotti MG, Scagliotti G. New strategies for targeting the therapy of NSCLC:  the role of ERCC1 and TS. Advances in Medical Sciences. 2010; 1:22-5.

Ceppi P**, Monica V, Righi L, Papotti M, Scagliotti GV. Emerging role of thymidylate synthase for the pharmacogenomic selection of patients with thoracic cancer. International Journal of Clinical  Pharmacology and Therapeutics. 2010; 7:481-2.

2009

Monica V, Scagliotti GV, Ceppi P, Righi L, Cambieri A, Lo Iacono M, Saviozzi S, Volante M, Novello S and Papotti M. Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. Clinical Cancer Research, 2009 15:7547-7552.

Scagliotti G, Ceppi P, Novello N, Papotti M. Chemotherapy Treatment Decisions in Advanced Non-   Small Cell Lung Cancer Based on Histology. ASCO Educational Book 2009.

Ceppi P**, Papotti M, Monica V, Lo Iacono M, Saviozzi S, Pautasso M, Novello S, Mussino S, Bracco E, Volante M, Scagliotti GV. Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin. Molecular Cancer Therapeutics 2009 Nov; 8 (11) :3066-74.

Volante M, Rosas R, Ceppi P, Rapa I, Cassoni P, Wiedenmann B, Settanni F, Granata R, Papotti M. Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. Journal of Pathology 2009;218(4):458-66.

Saviozzi S, Ceppi P, Novello S, Ghio P, Lo Iacono M, Borasio P, Cambieri A, Volante M, Papotti M, Calogero RA, Scagliotti GV. Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Research 2009 Apr 15;69:3390-6.

Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G, Scagliotti GV, Papotti M. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Modern Pathology 2009;22(5):709-17.

Scagliotti G, Ceppi P, Capelletto E, Novello S. Update Clinical Information For Multitargeted Antifolates. Clinical Lung Cancer 2009 Volume 10, p35-40.

Ceppi P**, Novello S, Cambieri A, Longo M, Monica V, Lo Iacono M, Giaj-Levra M, Saviozzi S, Volante M, Papotti M, Scagliotti GV. Polymerase η Messenger RNA Expression Predicts Survival of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Clinical Cancer Research 2009; 15:1039-45.

2008

Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV and Papotti M. Prognostic Role of Osteopontin Expression in Malignant Pleural Mesothelioma. American Journal of Clinical Pathology 2008 July 130 (1): 58-64.

Ceppi P, Longo M, Volante M, Novello S, Cappia S, Bacillo E, Selvaggi G, Saviozzi S, Calogero R, Papotti M and Scagliotti GV. Excision Repair Cross Complementing-1 and Topoisomerase IIalpha Gene Expression in Small-Cell Lung Cancer Patients Treated with Platinum and Etoposide. Journal of Thoracic Oncology, 2008 June 3(6): 583-9.

Rapa I, Ceppi P, Bollito E, Rosas R, Cappia S, Bacillo E, Porpiglia, Berruti A, Papotti M, Volante M. Human Ash1 Expression In Prostate Cancer With Neuroendocrine Differentiation. Modern Pathology. 2008 Jun 21 (6) 700-7.

Ceppi P**, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV, Papotti M. Thymidylate Synthase Expression In Gastroenteropancreatic And Pulmonary Neuroendocrine Tumors. Clinical Cancer Research. 2008 Feb 15;14(4):1059-64.

2007

Volante M, Saviozzi S, Rapa I, Ceppi P, Cappia S, Calogero R, Novello S, Borasio P, Papotti M, Scagliotti GV. Epidermal Growth Factor Ligand/Receptor Loop and Downstream Signaling Activation Pattern in Completely Resected Non-Small Cell Lung Cancer. Cancer. 2007 Sep 15 110 (6):1321-8.

2006

Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, Lo Iacono M, Cappia S, Papotti M, Scagliotti GV: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.

 
IZKF-Geschäftsstelle

Dr. Katrin Faber
Anne Reichel
Bianca Meyerhöfer-Klee

Kontakt

Telefon: 09131 85-46842
Fax: 09131 85-35903

zur IZKF-Geschäftsstelle

 
 
 
 
Bitte tragen Sie Ihren Namen und gültige E-Mail-Adresse(n) ein!
X zum Schließen

Zusammenfassung